tory burch reva Molecular targeted therapy of brea

px215467

Molecular targeted therapy of breast cancer and its research progress

In about 20% to 30% of advanced breast cancer have HER2 receptor overexpression. Survival rate of decline in HER2-positive patients, but also indicates some resistance to chemotherapy and endocrine therapy. Trastuzumab (Trastuzumab, Herceptin, Herceptin), is a humanized monoclonal antibody, the antibody is the first targeted therapy used in clinical medicine for the treatment of HER2-positive metastatic breast cancer . Trastuzumab alone for a 36% effective rate of ll, and the platinum drug, docetaxel, vinorelbine a synergistic effect with doxorubicin, paclitaxel, cyclophosphamide has additive effect,[link widoczny dla zalogowanych], but not with 5-fluorouracil with a antagonism. For overexpression of HER2 in advanced metastatic breast cancer,[link widoczny dla zalogowanych], standard treatment is the use of trastuzumab with the program. However, the epidermal growth factor receptor (EGFR) overexpression is also associated with poor prognosis of patients. Overexpression of HER2 in the cells, while inhibition of EGFR and HER2, have additive effect. Lapatinib is an oral small-molecule epidermal growth factor tyrosine kinase inhibitor, can act on the EGFR and HER2. Lapatinib also has high efficiency, and trastuzumab with no cross-resistance. Because of its small molecular structure, and trastuzumab is different from that through the blood-brain barrier, brain metastases of breast cancer have a therapeutic effect. Bevacizumab (Bevacizumab, Avastin) against vascular endothelial growth factor A (VEGF-A) subtype of recombinant human monoclonal antibody by multiple chemotherapy for metastatic breast cancer effective. II clinical trial showed that bevacizumab monotherapy clinical benefit for breast cancer was 17% (CR + PR + SD �� 6 months). Gefitinib is a powerful inhibitor of EGFR tyrosine kinase. Gefitinib to suppress resistance to endocrine therapy on a 7 cell line MCF growth. Gefitinib and tamoxifen combination, on a 7 cell line MCF better than single inhibition of Finland with his two-Mo. Molecular targeted therapy for breast cancer research in recent years, the most active areas, and there may be a major future direction of breast cancer drug research. With in-depth basic and clinical research, and will enable more patients with breast cancer benefit. �� Indica: Professor Liu Donggeng 'll,[link widoczny dla zalogowanych], l surname health delivery Professor Liu Jiwei ~ /, 3 Hospital of Qingdao Yi Professor Zhang Changyi / Lu Yong of Hubei Cancer Hospital, Imperial arsenic medical director Professor Yu Ding Yu-platinum Xiamen Xinhua Hospital, Dalian Medical University, Professor Wang Huaijin Abstract Beijing Cancer Hospital, melanoma, renal cell carcinoma to be a Glance Section Main Professor Ren Guojun Xiao / Professor Zhao Tiping more solutions, [= f; know good Professor Yang Shujun inch. Inch LUO Shi Yuankai City Southern Medical University Cancer Hospital, Chinese Academy of Medical Sciences Professor Shi Yuankai 2007.9No66 57 prescription drugs in China for a 7 / L,[link widoczny dla zalogowanych], a. A /, hand / oral treatment Si,[link widoczny dla zalogowanych], Austin �� - Field 1] I Dong Banzai into the development of sub-l ==. . The study of a cancer research for each of its L milk glands and shouted
More articles related to topics：

[link widoczny dla zalogowanych]

uggs bestellen _3705 Like flowers bloom in an inst

uggs bestellen TV art director of Quality and Trai